Medicus Pharma (NASDAQ: MDCX) announced positive interim results from its Phase 2 clinical study of SKNJCT-003, a non-invasive treatment for basal cell carcinoma (BCC). The interim analysis, conducted after randomizing over half of the targeted 60 patients, revealed a complete clinical clearance rate exceeding 60%. The investigational product, D-MNA, demonstrated good tolerability at both low (100µg) and high (200µg) doses, without serious adverse events or dose-limiting toxicities.
This positive interim data is a significant development in the BCC treatment landscape. Current treatment options for BCC can be invasive, involving surgical excision or other destructive methods. A non-invasive, topical treatment like SKNJCT-003 could offer a more patient-friendly approach, potentially improving treatment adherence and reducing the burden on healthcare systems. The strong clinical clearance rate observed in the interim analysis suggests that SKNJCT-003 could become a valuable addition to the current arsenal against BCC.
The interim analysis shows promising results for D-MNA’s efficacy and safety profile. Over 60% of patients achieved complete clinical clearance, indicating the potential for SKNJCT-003 to effectively eliminate BCC lesions. The absence of serious adverse events and dose-limiting toxicities further strengthens the product’s profile. Medicus plans to submit this interim data to the FDA for a Type C meeting in Q2 2025, aiming to discuss product development and expedite the clinical program, potentially seeking a fast-track designation.
This positive interim analysis positions Medicus to advance SKNJCT-003 through clinical development. A successful Type C meeting with the FDA could lead to an accelerated clinical pathway, potentially shortening the timeline to market. If the final study results confirm the interim findings, SKNJCT-003 could revolutionize BCC treatment, providing a more convenient and effective option for patients. This advancement also bolsters Medicus’s position in the dermatological oncology market, opening doors for further research and development of novel treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
